Effect of rapamycin on hepatic osteodystrophy in rats with portasystemic shunting

World Journal of Gastroenterology

Volumn 12, Issue 28, 2006, Pages 4504-4510

  van der Merwe, Schalk W ^a   Conradie, Maria M ^b   Bond, Robert ^a   Olivier, Brenda J ^a   Fritz, Elongo ^a   Nieuwoudt, Martin ^a   Delport, Rhena ^a   Slavik, Tomas ^c   Engelbrecht, Gert ^d   Kahn, Del ^d   Shephard, Enid G ^d   Kotze, Maritha J ^e   de Villiers, Nico P ^e   Hough, Stephen ^b  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c Department of Ampath Pathology ^*  (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e Christiaan Barnard Memorial Hospital   (South Africa)

Author keywords

Liver disease; Osteopenia; Portasystemic shunting; Rapamycin; T lymphocyte

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 1; INTERLEUKIN 6; RAPAMYCIN; SOMATOMEDIN C RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY GROWTH; BONE TURNOVER; CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HYPOGONADISM; LIVER OSTEODYSTROPHY; MALE; NONHUMAN; OSTEODYSTROPHY; OSTEOLYSIS; OSTEOPOROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PORTOSYSTEMIC ANASTOMOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; UPREGULATION; WEIGHT GAIN;

EID: 33747519579     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i28.4504     Document Type: Article

References (39)

1. Diamond T, Stiel D, Lunzer M, Wilkinson M, Roche J, Posen S. Osteoporosis and skeletal fractures in chronic liver disease. Gut 1990, 31: 82-87
2. Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003; 125: 941-966
3. van der Merwe SW, van den Bogaerde JB, Goosen C, Maree FF, Milner RJ, Schnitzler CM, Biscardi A, Mesquita JM, Engelbrecht G, Kahn D, Fevery J. Hepatic osteodystrophy in rats results mainly from portasystemic shunting. Gut 2003; 52: 580-585
4. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 304-309
5. Saito K, Ohara N, Hotokezaka H, Fukumoto S, Yuasa K, Naito M, Fujiwara T, Nakayama K. Infection-induced up-regulation of the costimulatory molecule 4-1BB in osteoblastic cells and its inhibitory effect on M-CSF/ RANKL-induced in vitro osteoclastogenesis. J Biol Chem 2004; 279: 13555-13563
6. Cenci S, Toraldo G, Weitzmann MN, Roggia C, Gao Y, Qian WP, Sierra O, Pacifici R. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci USA 2003; 100: 10405-10410
7. Toraldo G, Roggia C, Qian WP, Pacifici R, Weitzmann MN. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci USA 2003; 100: 125-130
8. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-342
9. Livshits G, Pantsulaia I, Trofimov S, Kobyliansky E. Genetic influences on the circulating cytokines involved in osteoclastogenesis. J Med Genet 2004; 41: e76
10. Weitzmann MN, Cenci S, Rifas L, Brown C, Pacifici R. Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood 2000; 96: 1873-1878
11. Roggia C, Tamone C, Cenci S, Pacifici R, Isaia GC. Role of TNF-alpha producing T-cells in bone loss induced by estrogen deficiency. Minerva Med 2004; 95:125-132
12. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, Takahashi K, Furuya T, Ishiyama S, Kim KJ, Saito S, Nishikawa T, Takahashi N, Togari A, Tornatsu T, Suda T, Kamatani N. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001; 44: 1003-1012
13. Benjamin IS, Ryan CJ, Engelbrecht GH, Campbell JA, van Hoorn-Hickman R, Blumgart LH. Portacaval transposition in the rat: definition of a valuable model for hepatic research. Hepatology 1984; 4: 704-708
14. Shephard GS, Carlini SM, Hanekom C, Labaclarios D. Analysis of 25-hydroxyvitamin D in plasma using solid phase extraction. Clin Chim Acta 1987; 167: 231-236
15. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987; 2: 595-610
16. Delport M, Maas S, van der Merwe SW, Laurens JB. Quantitation of hydroxyproline in bone by gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 804: 345-351
17. Bonjour JP, Ammann P, Chevalley T, Rizzoli R. Protein intake and bone growth. Can J Appl Physiol 2001; 26 Suppl: S153-166
18. Goya L, Garcia-Segura LM, Ramos S, Pascual-Leone AM, Argente J, Martin MA, Chowen JA. Interaction between malnutrition and ovarian hormones on the systemic IGF-I axis. Eur J Endocrinol 2002; 147: 417-424
19. Vyzantiadis T, Theodoridou S, Giouleme O, Harsoulis P, Evgeniclis N, Vyzantiadis A. Serum concentrations of insulin-like growth factor-I (IGF-I) in patients with liver cirrhosis. Hepatogastroenterology 2003; 50: 814-816
20. Van Thiel DH, Gavaler JS, Cobb CF, McClain CJ. An evaluation of the respective roles of portosystemic shunting and portal hypertension in rats upon the production of gonadal dysfunction in cirrhosis. Gastroenterology 1983; 85: 154-159
21. Cemborain A, Castilla-Cortazar I, Garcia M, Muguerza B, Delgado G, Diaz-Sanchez M, Picardi A. Effects of IGF-I treatment on osteopenia in rats with advanced liver cirrhosis. J Physiol Biochem 2000; 56: 91-99
22. Cemborain A, Castilla-Cortazar I, Garcia M, Quiroga J, Muguerza B, Picardi A, Santidrian S, Prieto J. Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment. J Hepatol 1998; 28: 122-131
23. Scharf JG, Schmitz F, Frystyk J, Skjaerbaek C, Moesus H, Blum WF, Ramadori G, Hartmann H. Insulin-like growth factor-I serum concentrations and patterns of insulin-like growth factor binding proteins in patients with chronic liver disease. J Hepatol 1996; 25: 689-699
24. Lozeva V, Valjakka A, Lecklin A, Olkkonen H, Hippelainen M, Itkonen M, Plumed C, Tuomisto L. Effects of the histamine H(1) receptor blocker, pyrilamine, on spontaneous locomotor activity of rats with long-term portacaval anastomosis. Hepatology 2000; 31: 336-344
25. Troen BR. Molecular mechanisms underlying osteoclast formation and activation. Exp Gerontol 2003; 38: 605-614
26. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Vallera DA. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines. J Immunol 1998; 160: 5355-5365
27. Vu MD, Amanullah F, Li Y, Demirci G, Sayegh MH, Li XC. Different costimulatory and growth factor requirements for CD4+ and CD8+ T cell-mediated rejection. J Immunol 2004; 173: 214-221
28. Barten MJ, Streit F, Boeger M, Dhein S, Tarnok A, Shipkova M, Armstrong VW, Mohr FW, Oellerich M, Gummert JF. Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of imummosuppression on lymphocyte proliferation and activation in rat whole blood. Transplantation 2004; 77: 1154-1162
29. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 531-562
30. Tian L, Lu L, Yuan Z, Lamb JR, Tam PK. Acceleration of apoptosis in CD4+CD8+ thymocytes by rapamycin accompanied by increased CD4+CD25+ T cells in the periphery. Transplantation 2004; 77:183-189
31. Cosmi L, Liotta F, Lazzeri E, Francalani M, Angeli R, Mazzinghi B, Santarlasci V, Manetti R, Vanini V, Romagnani P, Maggi E, Romagnani S, Annunziato F. Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. Blood 2003; 102:4107-4114
32. Xystrakis E, Dejean AS, Bernard I, Druet P, Liblau R, Gonzalez-Dunia D, Saoudi A. Identification of a novel natural regulatory CD8 T-cell subset and analysis of its mechanism of regulation. Blood 2004; 104: 3294-3301
33. Choi Y, Woo KM, Ko SH, Lee YJ, Park SJ, Kim HM, Kwon BS. Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. Eur J Immunol 2001; 31: 2179-2188
34. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000; 408: 600-605
35. Tsiavou A, Degiannis D, Hatziagelaki E, Koniavitou K, Raptis S. Flow cytometric detection of intracellular IL-12 release: in vitro effect of widely used immunosuppressants. Int Immunopharmacol 2002; 2:1713-1720
36. Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ 2003; 10: 1165-1177
37. Tokuda H, Hatakeyama D, Shibata T, Akamatsu S, Oiso Y, Kozawa O. p38 MAP kinase regulates BMP-4-stimulated VEGF synthesis via p70 S6 kinase in osteoblasts. Am J Physiol Endocrinol Metab 2003; 284: E1202-1209
38. Kozawa O, Matsuno H, Uematsu T. Involvement of p70 S6 kinase in bone morphogenetic protein signaling: vascular endothelial growth factor synthesis by bone morphogenetic protein-4 in osteoblasts. J Cell Biochem 2001; 81: 430-436
39. van der Poel HG, Hanrahan C, Zhong H, Simons JW. Rapamycin induces Smad activity in prostate cancer cell lines. Urol Res 2003; 30: 380-386